Non-opioid pill outperforms Vicodin in 343-patient trial
Phase 2b results published in the New England Journal of Medicine: LTG-001 eased post-surgical pain better than Vicodin, and half of the patients never took an opioid.
A phase 2b clinical trial published on July 29, 2026 in the New England Journal of Medicine reports that LTG-001, a non-opioid pill, controlled pain better than Vicodin in 343 patients recovering from abdominoplasty, or tummy tuck surgery. Vicodin, a fixed combination of hydrocodone and acetaminophen, has been the routine post-surgical prescription for decades. The trial was run by the American company Latigo Biotherapeutics and is registered as NCT07102459.
LTG-001 is a selective inhibitor of the voltage-gated sodium channel NaV1.8. That channel sits in the peripheral nervous system and carries pain signals toward the spinal cord, so blocking it damps the signal before it reaches the brain. Opioids work elsewhere, on receptors in the central nervous system, which is also where their addiction risk comes from.
NaV1.8 is not a new idea
The first drug in this class, suzetrigine, was approved by the US Food and Drug Administration (FDA) in January 2025 under the brand name Journavx, the first painkiller with a new mechanism of action in more than two decades. Its trials used the same surgical model, abdominoplasty, but the drug did not prove superior to the opioid combination there: it beat placebo, not hydrocodone with acetaminophen. That is why the comparison with Vicodin is the first number specialists look at in this trial.
How the trial was built
Patients with moderate to severe pain after abdominoplasty were randomly assigned to four equal groups, in a 1:1:1:1 ratio:
- high-dose LTG-001, a 450 mg loading dose then 300 mg every 12 hours
- low-dose LTG-001, a 300 mg loading dose then 150 mg every 12 hours
- the opioid comparator, 5 mg hydrocodone bitartrate with 325 mg acetaminophen every 6 hours
- placebo every 6 hours
The primary endpoint was SPID48, the summed difference in pain intensity measured over 48 hours after surgery. The higher the figure, the stronger the analgesic effect.
What the numbers say
The high dose produced an SPID48 of 62.1 against placebo, the low dose 37.8. According to the company, the high dose delivered roughly 50 percent greater analgesic effect than the opioid comparator over the first 48 hours.
Speed is the second finding. Median time to clinically meaningful pain relief was 52 minutes on the high dose, against 83 minutes on the opioid. Thirty-one minutes is a gap a patient with a fresh surgical wound will notice.
The third figure is the one closest to daily practice. Over the 48 hours, 52.3 percent of patients on the high dose took no opioid at all, against 22.1 percent on placebo. More than half of the high-dose group got through the first two days without a single hydrocodone tablet.
“This New England Journal of Medicine publication is a significant milestone for LTG-001,” Neil Singla, chief medical officer of Latigo Biotherapeutics, said in the company’s statement. Harold Minkowitz, a physician and investigator on the trial, said in the same statement: “The published LTG-001 results represent an important advance in the treatment of acute pain.”
Was the drug safe?
Adverse events were mostly mild to moderate, and the overall rate of adverse events was higher in the placebo group than in the groups receiving the drug. Two findings still count against it. Fever was recorded in 7 percent of patients on the high dose against 2 percent on placebo, and dizziness in 6 percent against 1 percent. With roughly 86 people per arm, rare adverse events simply cannot show up.
What the study does not prove
This is phase 2b, not phase 3. The trial measured one kind of pain, acute post-operative pain, after one kind of procedure, and only for 48 hours. It says nothing about chronic pain, about longer use, or about how the drug behaves in older patients or in people with impaired liver and kidney function. The data so far come from a trial funded by the manufacturer, with no independent replication.
LTG-001 is not approved in the United States or the European Union, and it is not on the drug register in Serbia. At least one large phase 3 trial has to be completed before regulators can rule, and those usually take years. What these results do establish is that blocking the NaV1.8 channel can outperform an opioid in one narrow, well-defined pain model. That is a concrete data point, not a licence to prescribe.
